

35. (Amended) An immobilized substantially pure modified heparinase III comprising:
a modified heparinase III as in claim 28, and
a solid support, wherein the modified heparinase III is immobilized on the solid support.

36. (Amended) A method of specifically cleaving a heparin-like glycosaminoglycan,
comprising:
contacting a heparin-like glycosaminoglycan with the modified heparinase III of claim 28.


REMARKS

Applicants have cancelled and revised claims prior to paying the filing fee. The claims are not narrowed in scope. Applicants reserve the right to pursue the cancelled or amended claims in the above-identified patent application or related divisional applications.

Respectfully submitted,

Liu et al., Applicant(s)

By:



Helen C. Lockhart, Reg. No. 39,248
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2211
Tel. No.: (617) 720-3500
Attorney for Applicant

Docket No. M0656/7063
Date: January 22, 2002
X01/19/02

MARKED-UP CLAIM

34. (Amended) A pharmaceutical preparation comprising a sterile formulation of the substantially pure heparinase III of claim [any one of claims] 28[-33] and a pharmaceutically acceptable carrier.

35. (Amended) An immobilized substantially pure modified heparinase III comprising: a modified heparinase III as in [any one of claims] claim 28[-33], and a solid support, wherein the modified heparinase III is immobilized on the solid support.

36. (Amended) A method of specifically cleaving a heparin-like glycosaminoglycan, comprising:

contacting a heparin-like glycosaminoglycan with the modified heparinase III of [any one of claims] claim 28[, 32, or 33].